Tuesday, August 27, 2019

Ascletis Received IND Approval for its NASH Drug

HANGZHOU, China and SHAOXING, China, Aug. 27, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today...



from PR Newswire: https://ift.tt/2ZpTzx5

No comments:

Post a Comment